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taking ratios of predicted prevalence rates for obese versus non-obese individuals.
Bootstrapped 95% confidence intervals were generated for prevalence ratios.
RESULTS: Among obese adults the unadjusted prevalence of hypertension was
(34.40%), followed by dyslipidemia (21.87%), diabetes (16.34%) and asthma (6.92%).
Adjusted prevalence of chronic diseases was always higher among obese as com-
pared to non-obese and the entire population. The prevalence ratio for diabetes
was 3.06 (95% C.I: 2.82 – 3.30) at the age of 20 and was 2.20 (95% C.I: 2.09 – 2.31) at 70
years. At any age, obesity increases the likelihood of these conditions by at least
50% as compared to non-obese individuals. CONCLUSIONS: Prevalence ratios in-
dicate that obesity has highest impact on prevalence of diabetes; followed by hy-
pertension, osteoarthritis, dyslipidemia. Study findings suggest that obesity is not
only a disease, but may also be a cause for other chronic disorders. There is a need
to develop effective interventions to combat obesity and thus minimize its impact
on other diseases in the United States.
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OBJECTIVES: Adherence to Food and Drug Administration recommended admin-
istration with adalimumab, etanercept, or infliximab may be variable. Suboptimal
adherence patterns may contribute to health care cost increases. This study esti-
mated incremental health care costs of tumor necrosis factor inhibitor (anti-TNF)
under-utilization from amanaged care perspective.METHODS:Medical/pharmacy
claims from the LifeLink™ Health Plan database were used. Inclusion criteria in-
cluded: index anti-TNF started January 1, 2004-December 31, 2007, age18 years, 2
pre-index rheumatoid arthritis diagnosis codes (ICD-9 code 714.xx), 365 days of
index drug, continuous enrollment 6/12months pre-/post-index. Exclusion criteria
included: switching biologics post-index and selected inflammatory conditions.
Under-utilization events were defined as prescriptions/infusions with 10% less
than recommended dosing for adalimumab (40 mg every other week/weekly with/
withoutmethotrexate), etanercept (50mgweekly), or infliximab (3mg/kg dose and
maintenance infusion interval  56 days). Incremental increases in health care
costs for patients with under-utilization, compared to receiving recommended
dosing, were estimated using cost regression models controlling for refill/infusion
intervals. Models were estimated for a 12-month time horizon and until index drug
discontinuation or loss of enrollment. RESULTS:A total of 4,586 RA patients receiv-
ing adalimumab (N1,255; 27,540 prescriptions), etanercept (N2,242; 48,517 pre-
scriptions), or infliximab (N1,089; 19,656 infusions) were included. Mean lengths
of time (days) patients received adalimumab (856), etanercept (881), and infliximab
(903) were comparable. Proportion of under-utilization events were 16%, 39%, and
2% for adalimumab, etanercept, and infliximab, respectively. Adalimumab or et-
anercept under-utilization was significantly associated with incremental in-
creased health care costs ($2,352 and $879; p0.01) for 12 months and through end
of data ($4,677 and $3,806; p0.01). Infliximabunder-utilizationwas infrequent and
not associated with increased health care costs. CONCLUSIONS: In this analysis,
adalimumab or etanercept under-utilization was associated with increased total
healthcare costs; however, infliximab under-utilization did not have a similar re-
sult. Additional research assessing clinical consequences of under-utilization is
warranted.
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OBJECTIVES:Golimumab is a 50milligram (mg), oncemonthly, injected anti-tumor
necrosis factor alpha therapy for treatment of rheumatoid arthritis, ankylosing
spondylitis and psoriatic arthritis. This study calculated expected costs of annual
golimumab therapy based upon observed dosing patterns within a SPP population
during the first 16 months of golimumab availability. METHODS: Pharmacy and
corresponding eNAVIGATORTM patient care management data were collected by
Diplomat Specialty Pharmacy, Flint, MI for adult patients with a golimumab pre-
scription between 4/24/2009 and 8/24/2010. Datawere analyzed statistically and are
reported as n, %, meanstandard deviation (SD) and median. Costs were modeled
in US dollars using the wholesale acquisition cost (WAC; effective 6/9/2010) of
$1,731.48 per 50 mg. RESULTS: The study included 89 patients. The majority were
female (65%); age 45 years (69%); and reported prior biologic use (56%). A 50 mg
golimumab dose was dispensed in 100% of patients and 100% of all doses. The
mean (SD) interval between golimumab doses was 32.0 14.1 days and the me-
dian was 28 days. The mean golimumab dosing interval in patients reporting bio-
logic use prior to golimumab initiation was 32.915.9 days (meanSD) and was
similar to the mean dosing interval observed in patients reporting no biologic use
prior to golimumab initiation (meanSD: 31.112.1 days; p0.15; NS). Based upon
modeling of these early observations, the average golimumab patient will utilize
approximately 11.4 doses of golimumab annually at a cost of $19,739 (WAC).
CONCLUSIONS: In this SPP population, all patients received 50 mg of golimumab.
The mean and median times between distribution of golimumab doses were 32
days and 28 days, respectively. Based upon the dosing and distribution patterns
observed, the estimated average annual per patient cost of golimumab would be
$19,739. Golimumab utilization may be similar for patients regardless of prior use
of biologic therapies.
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OBJECTIVES: To identify perceived benefits and disadvantages of intravenous in-
fusion (IV) biologic therapy among patients with immunology conditions currently
treated with IV biologic medication. METHODS: Semi-structured telephone inter-
views were conducted with patients self-reporting a diagnosis of ankylosing spon-
dylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, or ulcer-
ative colitis and currently receiving IV biologic therapy. Study protocol and
questionnaire were approved by an independent institutional review board. Pa-
tients rated satisfactionwith current IVmedication on a 7-point Likert scale, where
1 not at all satisfied and 7very satisfied. Patients also discussed benefits and
disadvantages of IV biologic therapy and reasons for IV preference. RESULTS: 405
interviews were conducted. Mean satisfaction was 6.1; 77% rated satisfaction as 6
or 7. The most frequently described benefits of IV therapy related to healthcare
professional monitoring and oversight at time of infusion. More than half of pa-
tients also experience a social benefit of IV administration, including talking to
other patients about experiences (56%) and tying-in other activities with infusion
facility visits (55%). Most commonly described disadvantages of infusion were du-
ration of infusion (41%) and scheduling issues (23%). Of current IV users,most (82%,
n332) prefer an IV medication to a subcutaneous injection. The most common
reasons for IV preference were: not wanting to self-inject (43%), less frequent dos-
ing (34%), and preference for healthcare professional administration (24%). Satis-
faction with medication and perceived benefits varied somewhat by demograph-
ics, immunologic condition, and factors related to treatment. CONCLUSIONS:
Current IV biologic users are highly satisfied with their medications. Patients per-
ceive the additional opportunity for healthcare provider interaction at infusion
facilities as a benefit of thismode of administration. These results support the need
for continued patient access to IV therapeutic options and shared decision-making
between patients and physicians when selecting biologic treatment.
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OBJECTIVES: Infliximab (IFX) is an infusible anti-tumor necrosis factor (anti-TNF)
drug used in the treatment of rheumatoid arthritis (RA), with Food and Drug Ad-
ministration (FDA) recommended administrations of 3 mg/kg at weeks 0, 2, 6, and
every 8 weeks thereafter. Dose increases up to 10 mg/kg or decreases in infusion
intervals to every 4 weeks may be appropriate based on individual response. Lim-
ited data are available presenting weight-based dosing, total quantity adminis-
tered, and infusion intervals simultaneously over the course of 30 infusions. The
objective of this studywas to calculateweight-based dosing, total quantity infused,
and infusion intervals for RA patients receiving IFX. METHODS: An event-level
analysis was conducted using medical/pharmacy claims from the IMS LifeLink™
Health Plan database. Inclusion criteria included: IFX initiation January 1, 2004-
December 31, 2007 (i.e., index date); patient age18 years old; 2 RA diagnosis codes
(ICD-9 714.xx); and 365 days of IFX persistence (i.e., number of days between first
and last IFX treatment). Patients were excluded if they had: psoriatic arthritis
(ICD-9 696.0), psoriasis (ICD-9 696.1), ulcerative colitis (ICD-9 556.xx), Crohn’s dis-
ease (ICD-9 555.xx), or ankylosing spondylitis (ICD-9 720.0); evidence of any anti-
TNF during the 6 months prior to index date; or evidence of taking abatacept or
rituximab while on IFX. RESULTS: There were 19,656 IFX infusion events (N1,089)
identified. Themedian weight-based doses spanned 3.0-4.2 mg/kg. Overall median
quantity infused at each infusion spanned 330-477 mg. Median infusion intervals
spanned 50-56 days for infusions 4-20. The median infusion intervals spanned
44-50 days for infusions 21-30. CONCLUSIONS: The observed IFX administration
schedule was consistent with FDA-approved prescribing of weight-based dosing
and infusion intervals over the course of 30 infusions. These data contribute to the
published literature by describing a consistent real-world administration schedule
over a longer period of time compared to other published studies.
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OBJECTIVES: Golimumab is the first and only monthly subcutaneous fully human
anti-TNF approved in the treatment of rheumatoid arthritis (RA), psoriatic arthritis
(PsA), and ankylosing spondylitis (AS). This study evaluated co morbidities and
pre-index biologic use among patients who received golimumab in the GE Centric-
ity® electronic medical records (EMR) database.METHODS: Longitudinal EMR data
were collected from outpatient practices in the United States. It contains clinical
information on over 15 million patients through September 2010. Patients were
selected based on the following criteria: 1ICD-9 diagnosis of RA, PsA, or AS; 18
years of age at the time of the first diagnosis; data 6-months prior and 3-months
after a prescription record of the first biologic, and at least one prescription record
for golimumab. Biologic experience was defined as use of a biologic within 6
months prior to the first golimumab record. RESULTS: A total of 153 [118 (RA); 20
(PsA); 15 (AS)] patients receiving golimumab were identified as meeting all the
inclusion criteria. The mean age was 49 years and 75% were female; 101 (66%)
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